ATE384053T1 - Triazolderivate als tachykininrezeptor- antagonisten - Google Patents

Triazolderivate als tachykininrezeptor- antagonisten

Info

Publication number
ATE384053T1
ATE384053T1 AT03723929T AT03723929T ATE384053T1 AT E384053 T1 ATE384053 T1 AT E384053T1 AT 03723929 T AT03723929 T AT 03723929T AT 03723929 T AT03723929 T AT 03723929T AT E384053 T1 ATE384053 T1 AT E384053T1
Authority
AT
Austria
Prior art keywords
tachykine
receptor antagonists
triazole derivatives
triazole
derivatives
Prior art date
Application number
AT03723929T
Other languages
English (en)
Inventor
Albert Amegadzie
Kevin Gardinier
Erik Hembre
Jian Hong
Louis Jungheim
Brian Muehl
David Remick
Michael Robertson
Kenneth Savin
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE384053T1 publication Critical patent/ATE384053T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/061,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT03723929T 2002-04-26 2003-04-22 Triazolderivate als tachykininrezeptor- antagonisten ATE384053T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37612102P 2002-04-26 2002-04-26

Publications (1)

Publication Number Publication Date
ATE384053T1 true ATE384053T1 (de) 2008-02-15

Family

ID=29270766

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03723929T ATE384053T1 (de) 2002-04-26 2003-04-22 Triazolderivate als tachykininrezeptor- antagonisten

Country Status (30)

Country Link
US (1) US7320994B2 (de)
EP (1) EP1501809B1 (de)
JP (1) JP4559087B2 (de)
KR (1) KR100755577B1 (de)
CN (1) CN1312136C (de)
AR (1) AR039329A1 (de)
AT (1) ATE384053T1 (de)
AU (1) AU2003230829B8 (de)
BR (1) BRPI0309534B8 (de)
CA (1) CA2483159C (de)
CR (1) CR7548A (de)
CY (1) CY1107221T1 (de)
DE (1) DE60318697T2 (de)
DK (1) DK1501809T3 (de)
EA (1) EA007720B1 (de)
EC (1) ECSP045391A (de)
ES (1) ES2298513T3 (de)
HR (1) HRP20041008B1 (de)
IL (2) IL164675A0 (de)
MX (1) MXPA04010622A (de)
MY (1) MY141559A (de)
NO (1) NO333647B1 (de)
NZ (1) NZ535886A (de)
PE (1) PE20040600A1 (de)
PL (1) PL212090B1 (de)
PT (1) PT1501809E (de)
TW (1) TWI265807B (de)
UA (1) UA79113C2 (de)
WO (1) WO2003091226A1 (de)
ZA (1) ZA200408670B (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
WO2005000821A1 (en) * 2003-06-12 2005-01-06 Eli Lilly And Company Tachykinin receptor antagonists
BRPI0415010B8 (pt) * 2003-10-24 2021-05-25 Lilly Co Eli formas cristalinas iv e v de {2-[1-(3,5-bis-trifluorometilbenzil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il)-(2-clorofenil)-metanona, (2-clorofenil)-[2-(2-hidróxi-2-piridin-4-il-vinil)piridin-3-il]metanona, seus processos de preparação, e composição farmacêutica sólida
CA2581454A1 (en) 2004-09-23 2006-03-30 Reddy Us Therapeutics, Inc. Novel pyrimidine compounds, process for their preparation and compositions containing them
WO2006083711A1 (en) * 2005-02-01 2006-08-10 Eli Lilly And Company Tachykinin receptor antagonists
EP1864980A4 (de) 2005-03-30 2010-08-18 Eisai R&D Man Co Ltd Ein pyridinderivat enthaltendes antipilzmittel
TW200716576A (en) * 2005-06-07 2007-05-01 Shionogi & Co Heterocyclic derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
CN101228137B (zh) * 2005-07-25 2010-09-29 弗·哈夫曼-拉罗切有限公司 被取代的三唑衍生物和它们作为神经激肽3受体拮抗剂的用途
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
NZ574153A (en) * 2006-08-18 2011-12-22 Syngenta Ltd Use of hppd inhibitors in the treatment of depression and/or withdrawal symptoms associated with addictive drugs
EP2065377B1 (de) 2006-09-21 2011-11-23 Eisai R&D Management Co., Ltd. Durch einen heteroarylring substituiertes pyridinderivat und antipilzmittel, das dieses enthält
BRPI0721069A2 (pt) 2006-12-20 2014-02-04 Lilly Co Eli Intermediários e processo útil na preparação de {2-[1-(3,5-bis-trifluorometil-benzil)-5-piridin-4-il-1h[1,2, 3]triazol-4-il]-piridin-3-il}-2-clorofenil)-metanona
WO2009019278A1 (en) * 2007-08-08 2009-02-12 Neurosearch A/S Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors
GB0722077D0 (en) 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
JP2011525915A (ja) * 2008-06-26 2011-09-29 アムジエン・インコーポレーテツド キナーゼ阻害薬としてのアルキニルアルコール類
GB0823002D0 (en) * 2008-12-17 2009-01-28 Syngenta Participations Ag Isoxazoles derivatives with plant growth regulating properties
WO2013004766A1 (en) 2011-07-04 2013-01-10 Ferrari Giulio Nk-1 receptor antagonists for treating corneal neovascularisation
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
ES2824552T3 (es) 2015-03-04 2021-05-12 Vanda Pharmaceuticals Inc Método de tratamiento con tradipitant
WO2017031215A1 (en) * 2015-08-17 2017-02-23 Eli Lilly And Company Process development of a pyridine-containing nk-1 receptor antagonist
DK3464271T3 (da) 2016-05-31 2020-06-15 Kalvista Pharmaceuticals Ltd Pyrazolderivater som plasma-kallikreininhibitorer
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
AU2018331267B2 (en) 2017-09-13 2024-03-07 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
CN119074729A (zh) * 2017-11-17 2024-12-06 万达制药公司 使用川地匹坦治疗胃肠疾病的方法
PT3716952T (pt) 2017-11-29 2022-04-14 Kalvista Pharmaceuticals Ltd Formas de administração que incluem um inibidor de calicreína plasmática
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
US20210015834A1 (en) 2018-02-26 2021-01-21 Ospedale San Raffaele S.R.L. Nk-1 antagonists for use in the treatment of ocular pain
CA3101210A1 (en) * 2018-06-08 2019-12-12 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
HUE070000T2 (hu) * 2018-09-28 2025-04-28 Vanda Pharmaceuticals Inc Tradipitant alkalmazása utazási betegségben
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
WO2020117811A1 (en) 2018-12-03 2020-06-11 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
WO2020132513A1 (en) 2018-12-21 2020-06-25 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
EP4010333A1 (de) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasmakallikreininhibitoren
KR20220145844A (ko) 2020-02-25 2022-10-31 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피탄트를 이용한 아토피 피부염의 개선된 치료
WO2021180885A1 (en) 2020-03-11 2021-09-16 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency
JP7791832B2 (ja) 2020-03-26 2025-12-24 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによる下気道感染症の治療
CA3173697A1 (en) 2020-04-03 2021-10-07 Mike TROWER An nk-1 receptor antagonist for treating a disease selecting from sepsis, septic shock, acute respiratory distress syndrome (ards) or multiple organ dysfunction syndrome (mods)
CN113563306B (zh) * 2020-04-28 2022-07-01 新发药业有限公司 一种2-(4-苯氧基苯基)-6-(哌啶-4-)基烟酰胺的制备方法
CA3177477A1 (en) 2020-06-02 2021-12-09 Nerre Therapeutics Limited Neurokinin (nk)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs
CN111662235B (zh) * 2020-06-23 2023-12-22 黄淮学院 一种苯甲酰基哒嗪衍生物及其制备方法
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
AU2023413130A1 (en) 2022-12-21 2025-06-05 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant
CN116082253B (zh) * 2023-02-25 2025-04-25 浙大城市学院 一种1-n-取代的1,2,3-三唑-4-甲酰胺衍生物及其制备方法
WO2024223617A1 (en) * 2023-04-24 2024-10-31 Fundamental Pharma Gmbh Effective means to modulate nmda receptor-mediated toxicity
EP4599831A1 (de) 2024-02-09 2025-08-13 Vanda Pharmaceuticals Inc. Behandlung von gastroparese mit tradipitant

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL50699A0 (en) 1975-10-28 1976-12-31 Ici America Inc Triazole derivatives
WO1995011880A1 (en) * 1993-10-27 1995-05-04 Merck Sharp & Dohme Limited Substituted amides as tachykinin antagonists
US6175013B1 (en) * 1994-06-10 2001-01-16 Eli Lilly And Company Imidazolinyl tachykinin receptor antagonists
US5998444A (en) 1995-10-24 1999-12-07 Zeneca Ltd. Piperidinyl compounds as NK1 or NK2 antagonists
WO1997040025A1 (en) 1996-04-19 1997-10-30 Novo Nordisk A/S Solid phase and combinatorial synthesis of substituted 1,2,3-triazoles and of arrays of substituted 1,2,3-triazoles
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
HU229024B1 (en) * 1996-07-24 2013-07-29 Bristol Myers Squibb Pharma Co Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
TR200000291T2 (tr) 1997-08-06 2000-07-21 Eli Lilly And Company Taşikinin reseptör antagonistleri olarak 2-asilaminopropanaminler.
ES2258485T3 (es) * 1999-12-17 2006-09-01 Schering Corporation Antagonistas selectivos de neuroquinina.
TWI287003B (en) 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
DE10036818A1 (de) * 2000-07-28 2002-02-07 Solvay Pharm Gmbh Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten
JP2002123925A (ja) 2000-10-13 2002-04-26 Fuji Photo Film Co Ltd 磁気記録媒体
ES2307925T3 (es) * 2002-04-26 2008-12-01 Eli Lilly And Company Antagonistas de los receptores de la taquiquinina.

Also Published As

Publication number Publication date
KR20040104634A (ko) 2004-12-10
TWI265807B (en) 2006-11-11
HRP20041008B1 (hr) 2012-10-31
IL198122A0 (en) 2009-12-24
TW200306824A (en) 2003-12-01
UA79113C2 (en) 2007-05-25
US20050239786A1 (en) 2005-10-27
JP2005536458A (ja) 2005-12-02
DE60318697D1 (de) 2008-03-06
PL373504A1 (en) 2005-09-05
AU2003230829B8 (en) 2008-12-11
CN1312136C (zh) 2007-04-25
EP1501809B1 (de) 2008-01-16
PT1501809E (pt) 2008-03-18
PL212090B1 (pl) 2012-08-31
AR039329A1 (es) 2005-02-16
CA2483159A1 (en) 2003-11-06
CA2483159C (en) 2010-08-10
NZ535886A (en) 2007-07-27
IL164675A0 (en) 2005-12-18
MXPA04010622A (es) 2005-01-25
EA200401431A1 (ru) 2005-06-30
US7320994B2 (en) 2008-01-22
ES2298513T3 (es) 2008-05-16
KR100755577B1 (ko) 2007-09-12
DK1501809T3 (da) 2008-05-13
PE20040600A1 (es) 2004-09-15
JP4559087B2 (ja) 2010-10-06
ECSP045391A (es) 2005-01-03
CY1107221T1 (el) 2012-11-21
BRPI0309534B8 (pt) 2021-05-25
NO333647B1 (no) 2013-07-29
EA007720B1 (ru) 2006-12-29
AU2003230829B2 (en) 2008-12-04
CR7548A (es) 2006-12-01
DE60318697T2 (de) 2009-01-08
BR0309534A (pt) 2005-02-01
CN1646502A (zh) 2005-07-27
NO20045120L (no) 2004-12-07
EP1501809A1 (de) 2005-02-02
ZA200408670B (en) 2005-10-26
WO2003091226A1 (en) 2003-11-06
MY141559A (en) 2010-05-14
AU2003230829A1 (en) 2003-11-10
HRP20041008A2 (en) 2004-12-31
BRPI0309534B1 (pt) 2017-11-07
HK1073304A1 (en) 2005-09-30

Similar Documents

Publication Publication Date Title
ATE384053T1 (de) Triazolderivate als tachykininrezeptor- antagonisten
CY2017032I1 (el) Παραγωγα (θειο)καρβαμοϋλ-κυκλοεξανιου ως ανταγωνιστες των υποδοχεων d3/d2
ATE344798T1 (de) Als histamin-h3-antagonisten geeignete indolderivate
NO20051871D0 (no) Opioid reseptorantagonister
ATE328871T1 (de) 4-phenyl-pyridin-derivate verwendbar als neurokinin-1 rezeptor antagonisten
ATE413400T1 (de) Cgrp-rezeptorantagonisten
IS7625A (is) Nýjar samrunnar imídazól afleiður
DE60331751D1 (de) N-substituierte 2-oxodihydropyridinderivate als npy antagonisten
DE60023167T2 (de) Pyrazol-derivate als cannabinoidrezeptor-antagonisten
PL373889A1 (en) (1-4-piperidinyl)benzimidazole derivatives useful as histamine h3 antagonists
DE60316411D1 (de) Thiazolderivate als npy-rezeptorantagonisten
ATE432282T1 (de) 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten
ATE377008T1 (de) Imidazolderivate als glutamatrezeptorantagonisten
ATE518834T1 (de) 2,3,4,9-tetrahydro-1h-carbazol-derivative als crth2-rezeptorantagonisten
ATE338043T1 (de) 5-methoxy-8-aryl- 1,2,4ötriazolo 1,5-aöpyridine derivative als adenosin-rezeptor antagonisten
ATE495168T1 (de) Heteroarylsubstituierte imidazolderivate als glutamatrezeptorantagonisten
ATE504300T1 (de) Harnstoffderivate als il-8-rezeptorantagonisten
NO20033223L (no) Histamin-reseptor antagonister
ATE528291T1 (de) Cyclopropylderivate als nk3 rezeptor-antagonisten
ATE320254T1 (de) Crf receptor antagonisten
DE602004018527D1 (de) Furanderivate als ep4-rezeptorantagonisten
SI1501809T1 (sl) Derivati triazola kot antagonisti tahikininskega receptorja

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1501809

Country of ref document: EP